SEC Company Response from AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818) (AYTU) — Oct 26, 2016
AYTU BIOPHARMA, INC (AYTU) (CIK 0001385818)
Date: Oct. 26, 2016 · CIK: 0001385818 · Accession: 0001144204-16-129654
AI Filing Summary & Sentiment
File numbers found in text: 333-213738
Show Raw Text
CORRESP
1
filename1.htm
JOSEPH GUNNAR & CO., LLC
30 Broad Street, 11th Fl
New York, NY 10004
October 26, 2016
Via EDGAR Delivery
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re: Aytu BioScience, Inc.
Registration Statement on Form S-1
Filed September 21, 2016
File No. 333-213738
Ladies and Gentlemen:
Pursuant to Rule 461
of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended
(the “Securities Act”), we, the representative of the several underwriters (the “Representative”), hereby
join in the request of the Company that the effective time of the above-referenced Registration Statement be accelerated so that
it will be declared effective at 5:00 p.m. Eastern Time on Thursday, October 27, 2016, or as soon thereafter as practicable.
Pursuant to Rule
460 under the Securities Act, please be advised that during the period from October 11, 2016 to the date of this letter, we,
acting on behalf of the several underwriters, distributed as many copies of the Preliminary Prospectuses, dated October 11,
2016 and October 25, 2016 as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.
Very truly yours,
JOSEPH GUNNAR & CO., LLC
By: /s/ Eric Lord
Name: Eric Lord
Title: Head of Investment
Banking/Underwritings